Article (Published version) (385 Kb) - Free access
The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT.
|Published in||Bone Marrow Transplantation. 2014, vol. 49, no. 1, p. 55-61|
|Abstract||Several T-cell depletion (TCD) techniques are used for haploidentical hematopoietic SCT (HSCT), but direct comparisons are rare. We therefore studied the effect of in vitro TCD with graft engineering (CD34 selection or CD3/CD19 depletion, 74%) or in vivo TCD using alemtuzumab (26%) on outcome, immune reconstitution and infections after haploidentical HSCT. We performed a retrospective multicenter analysis of 72 haploidentical HSCT in Switzerland. Sixty-seven patients (93%) had neutrophil engraftment. The 1-year OS, TRM and relapse incidence were 48 (36-60)%, 20 (11-33)% and 42 (31-57)%, respectively, without differences among the TCD groups. In vivo TCD caused more profound lymphocyte suppression early after HSCT, whereas immune recovery beyond the second month was comparable between the two groups. Despite anti-infective prophylaxis, most patients experienced post-transplant infectious complications (94%). Patients with in vivo TCD had a higher incidence of CMV reactivations (54% vs 28%, P=0.015), but this did not result in a higher TRM. In conclusion, TCD by graft engineering or alemtuzumab are equally effective for haploidentical HSCT.|
|Research group||Plateforme d'oncologie et d'hématologie pédiatrique (907)|
|MAREK, A et al. The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT. In: Bone Marrow Transplantation, 2014, vol. 49, n° 1, p. 55-61. doi: 10.1038/bmt.2013.132 https://archive-ouverte.unige.ch/unige:37150|